A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial Investigating the Safety and Efficacy of C21 in Hospitalised Subjects With COVID-19 Infection Not Requiring Mechanical Ventilation
Latest Information Update: 07 Oct 2022
At a glance
- Drugs Buloxibutid (Primary)
- Indications COVID-19 respiratory infection; Inflammation; Respiratory insufficiency
- Focus Therapeutic Use
- Acronyms ATTRACT
- Sponsors Vicore Pharma
Most Recent Events
- 29 Aug 2022 Results assessing short-term C21 treatment decreased the release of NT-proBNP in subjects hospitalised with COVID-19, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
- 02 Nov 2021 Results presented in the Vicore Pharma Media Release.
- 25 Oct 2021 Results published in Vicore Pharma Media Release.